SEC Comment Letter for INOVIO PHARMACEUTICALS, INC. (INO) (CIK 0001055726) (INO) — Nov 16, 2023

INOVIO PHARMACEUTICALS, INC. (INO) (CIK 0001055726)
Date: Nov. 16, 2023 · CIK: 0001055726 · Accession: 0000000000-23-012564

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-275445

Date

November 16, 2023

Author

Jacqueline Shea

Form

UPLOAD

Company

INOVIO PHARMACEUTICALS, INC. (INO) (CIK 0001055726)

Letter

United States securities and exchange commission logo November 16, 2023 Jacqueline Shea President and Chief Executive Officer Inovio Pharmaceuticals, Inc. 660 West Germantown Pike, Suite 110 Plymouth Meeting, PA 19462 Re:Inovio Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed November 9, 2023 File No. 333-275445 Dear Jacqueline Shea: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Nicholas O'Leary at 202-551-4451 with any questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services cc: Brian Leaf, Esq.

Show Raw Text

United States securities and exchange commission logo
November 16, 2023
Jacqueline Shea
President and Chief Executive Officer
Inovio Pharmaceuticals, Inc.
660 West Germantown Pike, Suite 110
Plymouth Meeting, PA 19462
Re:Inovio Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed November 9, 2023
File No. 333-275445
Dear Jacqueline Shea:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Nicholas O'Leary at 202-551-4451 with any questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc:       Brian Leaf, Esq.

SecProbe.io